PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Bleeding May Outpace Ischemic Recurrence in Young Stroke Survivors

aspirinclopidogrelticagrelordipyridamoleantiplatelet therapydirect oral anticoagulantsvitamin K antagonistslow-molecular-weight heparinischemic strokeyoung adultssecondary preventionbleeding riskcardioembolic strokepatent foramen ovalecohort studyODYSSEY Anticoagulation / Hematology

Background Information

Young stroke survivors face significant bleeding risk on antithrombotic therapy.

The study addresses the balance between the benefits and risks of antithrombotic therapy in young adults after ischemic stroke, focusing on bleeding risk. Among 1226 young stroke survivors, the 5-year cumulative risk of bleeding was 10.7%, with an annual rate of 2.5 events per 100 person-years. Results suggest that bleeding risks can surpass recurrent vascular events in young stroke survivors on long-term antithrombotic therapy, emphasizing the need for careful risk assessment. Long-term antithrombotic therapy in young stroke survivors comes with notable bleeding risks that should be carefully managed.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Rasing A, Verburgt E, Ekker MS, Schellekens MMI, Immens MHM, Verhoeven JI, Boot EM, van Alebeek ME, Brouwers PJAM, Arntz RM, van Dijk GW, van Uden IWM, Gons RAR, den Heijer T, van Tuijl JH, de Laat KF, van Norden AGW, Vermeer SE, van Zagten MSG, van Oostenbrugge RJ, Wermer MJH, Nederkoorn PJ, Kerkhoff H, Rooyer FA, van Rooij FG, van den Wijngaard IR, Ten Cate TJF, Tuladhar AM, Richard E, de Leeuw FE, Hilkens NA

Citation: Rasing A, Verburgt E, Ekker MS, et al. Antithrombotic Therapy and Bleeding Risk Among Young Adults After Ischemic Stroke. JAMA network open. 2026;9(9):e2635826. doi:10.1001/jamanetworkopen.2026.35826

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.